Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection
Date:5/28/2009

Year Ended Year Ended March 31, March 31, 2009 2008 Net sales $337,177,482 $350,366,689 Cost of goods sold 269,382,927 265,651,539 Gross profit 67,794,555 84,715,150 Selling, general and administrative expenses 16,417,971 14,322,140 Research and development costs - affiliate - 11,320,640 Research and development costs - other 22,527,504 18,366,306 Operating income 28,849,080 40,706,064 Other income (expense) Interest income 631,151 1,832,409 Interest expense (28,294) - Loss on sale of equipment - (144,551) Other income - net 602,857 1,687,858 Net income before income taxes 29,451,937 42,393,922 Income tax expense 8,915,358 7,005,817 Net income $20,536,579 $35,388,105 Net income per common share Basic $ 0.60 $ 1.19 Diluted $ 0.51 $ 0.89 Weighted number of shares Basic 34,227,335 29,656,624 Diluted 40,575,721 39,913,754


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
(Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... devouring billions of dollars globally, Alzheimer,s disease is the ... Although intensely investigated over the last three decades using ... not been found. While many research "breakthroughs" have ... does the promised "cure" still seem to elude scientists? ...
... (HealthDay News) -- Good news for high-mileage runners: They may be ... because variations in diet are less likely to affect them, researcher ... grouped according to the distance they run each day: less than ... to 4 km); 2.4 to 3.7 miles (4 to 6 km); ...
... published research shows that more patients with end-stage ... hemodialysis as their initial kidney replacement therapy over ... the study now available in Arthritis Care ... College of Rheumatology (ACR), also found that African ...
... device that combines two microimaging technologies can reveal ... biological activities that, in coronary arteries, could indicate ... of clots in arterial stents. In their ... Massachusetts General Hospital (MGH) investigators describe using an ...
... Special Surgery physician-scientists who focus on arthritis, lupus, vasculitis ... to Chicago this week to share their recent findings ... College of Rheumatology (ACR). Special Surgery investigators will ... care. Of the meeting,s highlights, results from the nine-year ...
... appear to be stopping anti-TNF medications before surgery, but may ... a new study by researchers at Hospital for Special Surgery. ... diseases, including rheumatoid arthritis, and better timing of withdrawal prior ... "We need to do more studies to see ...
Cached Medicine News:Health News:New study challenges accepted approaches to research in senile dementia (Alzheimer's disease) 2Health News:New study challenges accepted approaches to research in senile dementia (Alzheimer's disease) 3Health News:Runners Can Relax About Holiday Feasting: Study 2Health News:Most lupus nephritis patients with end-stage renal disease opt for hemodialysis therapy 2Health News:Combined arterial imaging technology reveals both structural and metabolic details 2Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 2Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 3Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 4Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 5Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 6Health News:Tweaking withdrawal of rheumatoid arthritis medications before surgeries may reduce disease flares 2Health News:Tweaking withdrawal of rheumatoid arthritis medications before surgeries may reduce disease flares 3
(Date:1/23/2015)... 2015  Now available for sale, The Armor1 Ankle Roll ... ankle sprains by cushioning the ankle from an inversion ... the outside of any shoe type and allows the ... offering protection against sprains. With customers in physical therapy, ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/22/2015)... 2015  ViewRay™, a privately held medical device company, announced ... agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) ... treatment of cancer in Japan . ... first and only MRI-guided radiation therapy system that images ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: